Kazakhstan’s new cancer treatment capacity adds weight to its medical tourism pitch. Comparing destinations still means looking beyond low prices, hospital badges and national patient totals.
A proton therapy center in Astana gives Kazakhstan something tangible to show patients considering cancer care abroad. It also raises a harder question: when should someone choose Kazakhstan over Türkiye, South Korea or neighboring Uzbekistan?
There is no credible answer that ranks all four countries from best to worst. A patient looking for dental treatment faces a different decision from someone seeking radiation therapy. Even within one specialty, the relevant comparison is usually between specific clinical teams.
National figures can still provide context. They show the approximate scale of each market and where governments have invested. What they cannot do is establish a standard price, prove superior results or tell a patient whether a particular treatment is needed.
Four destinations, different kinds of scale
Kazakhstan’s authorities reported approximately 80,000 foreign patients for 2025. Türkiye’s official health tourism agency, USHAŞ, lists almost 1.4 million healthcare visitors for the same year. South Korea’s Medical Korea portal reports approximately 2.01 million foreign patients, while Uzbekistan’s statistics agency records 86,199 foreign citizens arriving for treatment.
Those are the sources’ own measures. They should not be treated as a harmonized international ranking.
| Destination | Reported volume | What the source describes |
|---|---|---|
| Kazakhstan | Approximately 80,000 | Foreign patients received by medical organizations; the announcement does not provide a detailed counting method. |
| Turkey | 1,398,580 | Visitors receiving healthcare services, in USHAŞ data sourced to the Turkish Statistical Institute. |
| South Korea | Approximately 2.01 million | Foreign patients from 201 countries, as reported by Medical Korea. |
| Uzbekistan | 86,199 | Foreign citizens arriving for medical treatment, according to the National Statistics Committee. |
Large differences in reported volume suggest that Kazakhstan is still operating on a much smaller scale than Türkiye and South Korea. The figures alone do not show how many visitors underwent surgery, received a brief outpatient service or returned for another course of care.
They also do not measure safety. A larger patient count can reflect a wider range of services or stronger marketing, without telling us anything about the results of one hospital’s cancer program.
Uzbekistan’s total is particularly relevant to Kazakhstan’s regional ambitions. A nearby country with a substantial treatment-travel market cannot be dismissed merely because it receives less attention in international hospital advertising.
Why a national price league table would mislead
Claims that Kazakhstan is a fixed percentage cheaper than Türkiye or South Korea sound useful. They become much less useful when the underlying comparison lacks named providers, dated quotations and a common treatment package.
The sources reviewed for this article did not establish a reliable four-country price comparison for equivalent cardiac surgery, IVF or proton therapy. Publishing a percentage discount would therefore create a precision the available evidence cannot support.
A fair comparison starts with the same clinical problem. A hospital that has reviewed the patient’s records may quote for a different procedure from a clinic responding to a short online inquiry. Those prices are not necessarily competing offers for the same care.
Take IVF as an example of what a quotation needs to explain. Does the price include medication, laboratory services and the planned embryo transfer? What happens financially if the clinical plan changes? Are storage and later visits separate? A headline price cannot answer those questions.
For surgery, the same exercise involves the surgeon’s fee, anesthesia, the implant if one is needed, the planned hospital stay and the terms for additional care. The comparison becomes meaningful only when the inclusions and exclusions are written down.
Travel belongs in that calculation too. An illustrative patient whose treatment requires a second visit might save on the first hospital bill but pay more for repeat flights, accommodation and time away from work. This does not make overseas care poor value; it changes what “value” has to include.
Currency is another source of confusion. A quote should state the billing currency, how long it remains valid and the rules for changing or canceling treatment. A conversion shown on a marketing page may not be the amount ultimately charged.
Kazakhstan’s strongest new claim is specific
The government’s November 2025 account of Astana’s oncology center described a proton therapy facility equipped with a ProBeam 360 system and designed for up to 1,000 patients annually. It identified the facility as the only center in Central Asia with that system.
This gives Kazakhstan a distinct regional service to discuss with referring doctors. It does not establish that the country is superior across cancer care, or that every foreign patient can obtain a place immediately.
Proton therapy is a form of radiation treatment. As the US National Cancer Institute explains, the physical properties of proton beams can limit radiation exposure beyond the tumor. Researchers continue to compare proton and photon treatments in clinical trials.
That is a reason for a specialist discussion, not a reason to choose treatment from the name of the machine. Patients should ask why the proposed approach fits their cancer and what evidence supports it compared with the available alternatives.
The distinction is especially relevant to medical travel. A family may focus on gaining access to a rare technology while overlooking the rest of the proposed care: consultations, treatment planning, the likely length of the stay and follow-up arrangements.
For Kazakhstan, the opportunity is to build a clear referral service around a defined clinical capability. Advertising “advanced cancer care” is broad. Explaining which cases a team accepts, how it assesses them and how it communicates with the referring doctor is far more useful.
Accreditation helps when patients check the right thing
Kazakhstan’s tourism minister reported ten JCI-accredited medical organizations at a June 2026 government meeting. This is an official, dated count, rather than a current registry audit conducted for this article.
Comparing that figure with undated totals for other countries would be a weak way to judge quality. Accreditation can apply to different organizations and programs; it must be checked at the facility level.
The JCI directory is a better starting point than a badge copied onto an agent’s website. Patients need to identify the exact institution where their care will take place.
The CDC puts the limitation plainly: “accreditation does not guarantee a good outcome.” Its medical tourism guidance also stresses research into the individual provider and professional qualifications.
A practical comparison would therefore ask each hospital about the proposed clinician, the team’s experience with the specific procedure and the results it can document. A national accreditation total answers none of those questions on its own.
Nor should a hospital’s success percentage be accepted without explanation. Which patients are included? Over what period? What counts as success? Two hospitals can publish different-looking results because they treat different cases or measure different outcomes.
Fertility care illustrates the problem. The UK’s Human Fertilisation and Embryology Authority publishes separate measures for pregnancies and births, with information by age and by treatment cycle or embryo transfer. Its figures concern UK clinics, not a ranking of these four destinations. The reporting approach is useful because it shows why the words “success rate” need a definition.
A couple comparing clinics in Almaty and Istanbul should not be asked to choose between two large percentages without knowing whether the clinics measured the same result in comparable patients. A clear explanation can be more valuable than the apparently higher number.
South Korea offers a model for checking providers
South Korea’s relevance goes beyond its large reported patient total. Its official system for institutions serving foreign patients provides a concrete verification step: registration. Medical Korea states that registered medical institutions have been required to hold medical malpractice liability insurance since 2016.
Patients can also distinguish that registration system from the separate Korean accreditation program for hospitals serving foreign patients. These are specific arrangements, not simply a claim that a country has good doctors.
That does not remove the need to understand the provider’s contract or the limits of an insurance policy. It does show why the organization of medical travel belongs in a destination comparison alongside treatment technology.
For Kazakhstan, the lesson is practical. A visitor should be able to establish who is authorized to provide the treatment, who is arranging it and where to raise a concern. The simpler those checks become, the easier it is to compare an unfamiliar hospital fairly.
Türkiye’s scale does not make every package equivalent
USHAŞ’s figures show an established healthcare-travel business in Türkiye, with roughly $3.02 billion in reported revenue in 2025. They also show that visitor numbers were below the 2024 total of about 1.51 million.
That makes Türkiye a useful reminder that a large medical tourism market does not automatically grow every year. National performance depends on more than the construction of hospitals or the appeal of a destination brand.
For the patient comparing an offer in Istanbul with one in Astana, the immediate task is narrower. Which hospital will actually perform the treatment? Has the clinical team assessed the case? Does the quotation come from that hospital or from a separate business arranging the trip?
Accommodation and airport transport may make a package easier to organize. They do not resolve uncertainty about the procedure, the expected recovery or responsibility for extra costs.
A smaller destination can compete on clear answers to those questions. It does not need to claim that every service is cheaper or that a lower national patient total means more personal care.
Uzbekistan changes the regional comparison
Uzbekistan’s 2025 data show a market heavily connected to its neighbors. The official tally includes 59,145 arrivals from Tajikistan and 15,631 from Kyrgyzstan for treatment.
Those figures make geographical access part of the competitive picture. Kazakhstan is not the only option for patients who want to stay within Central Asia.
The release does not establish why each visitor chose Uzbekistan, what they paid or how their treatment turned out. It would be wrong to turn the figures into a claim that Uzbekistan is always cheaper, or that its patients are seeking only basic care.
Instead, they point to the need for more precise questions. Which cities are patients traveling between? Which services are difficult to obtain locally? How many visits does a course of treatment require? Those details would explain competition better than a broad contest between national brands.
The useful comparison fits on a treatment plan
The journey home also changes the comparison. The NHS treatment-abroad checklist makes aftercare and possible complications part of the decision before booking. Although its funding guidance is specific to UK patients, the underlying planning questions have wider relevance.
Suppose two hospitals offer similar treatment prices. One provides a defined follow-up appointment, an agreed method for sending results and a named clinical contact. The other leaves those arrangements to the patient. Their services are not equivalent, even if the initial procedures are.
Distance matters differently depending on the care plan. A shorter journey may make a return visit easier, but it cannot compensate for a clinic that has no clear process for reassessment. Likewise, an online consultation may help maintain contact while still leaving the patient in need of an examination close to home.
These are service terms that patients can ask providers to explain in writing. They also offer a fairer basis for comparison than assumptions about which nationality of doctor will communicate best or which destination will provide the most personal attention.
Kazakhstan’s most credible position is specific: a provider with an appropriate service, a clinical team that can explain its work and a trip the patient can reasonably manage. That offer may be attractive even when Kazakhstan has fewer international patients than a competitor.
The patient’s comparison should bring three documents together: the clinical recommendation, the itemized quotation and the follow-up plan. If one is missing, a cheaper package or a more impressive hospital website cannot fill the gap.
Before paying a deposit, the most revealing question may be a simple one: after the final appointment, who takes responsibility for explaining what happens next?
